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OBJECTIVE — The purpose of this study was to examine the effect of type of insulin analog
and age of insertion site on the pharmacodynamic characteristics of a standard insulin bolus in
youth with type 1 diabetes receiving insulin pump therapy.
RESEARCH DESIGN AND METHODS — Seventeen insulin pump–treated adoles-
centswithtype1diabetesunderwenttwoeuglycemicclampproceduresaftera0.2unit/kgbolus
of either insulin aspart or lispro on day 1 and day 4 of insulin pump site insertion. The glucose
infusion rate (GIR) required to maintain euglycemia was the primary pharmacodynamic mea-
sure.
RESULTS — Therewerenostatisticallysigniﬁcantdifferencesinanyofthepharmacodynamic
parameters between aspart and lispro during day 1 and day 4. However, when the two groups
were combined, time to discontinuation of exogenous glucose infusion, and time to half-
maximal onset and offset of insulin action were observed signiﬁcantly earlier during day 4
compared with day 1 (P  0.03–0.0004), but the overall area under the GIR curve was similar
on day 1 and day 4.
CONCLUSIONS — With both insulin aspart and lispro, there is an earlier peak and shorter
duration of action with increasing duration of infusion site use, but overall insulin action is not
affected.
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A
s a result of the Diabetes Control
and Complications Trial and its fol-
low-up Epidemiology of Diabetes
Interventions and Complications study,
current recommendations mandate that
youth with type 1 diabetes should aim to
achieve metabolic control as close to nor-
mal as possible and as early in the course
of the disease as possible. Although such
strict treatment goals are particularly dif-
ﬁculttoachieveinadolescentswithtype1
diabetes (1–3), advances in insulin pump
technology and the development of rap-
id-acting insulin analogs have provided
clinicians who treat adolescents with type
1 diabetes with new management tools.
With continuous subcutaneous insu-
lin infusion (CSII) pump therapy, bolus
doses of rapid-acting insulin analogs pro-
vide better control of postprandial hyper-
glycemia without increasing the risk of
hypoglycemia in comparison to what can
beachievedwithregularinsulin(4–9).In
addition, the newest insulin pumps ac-
count for residual insulin action in their
bolus calculator software to prevent hy-
poglycemia related to multiple bolus
doses given over a short interval. How-
ever, the duration and decay curves of in-
sulin action programmed into these
systems are based on small numbers of
adult patients, because the data regarding
the pharmacodynamic properties of rapid-
acting insulin analogs in CSII-treated
youth with type 1 diabetes were not
available.
Using the euglycemic glucose clamp
technique to describe the time-action
proﬁle of insulin in adolescents with type
1diabetes,werecentlydemonstratedthat
the peak action of insulin aspart is not
observeduntil90minafterastandardbo-
lus dose of 0.2 unit/kg, a full 40 min after
the peak plasma insulin concentrations
are achieved (10). It is important to note
thatallofthesestudieswereperformedin
insulin pump–treated patients 12 h af-
ter insertion of a new infusion set cathe-
ter.Surprisingly,theeffectsofdurationof
infusionsetuseonthepharmacodynamic
properties of rapid-acting insulin analogs
in youth with type 1 diabetes have not
been studied. Consequently, the recom-
mendations that patients change their in-
fusion sites every 2–4 days are based
primarily on anecdotal reports of increas-
ing glucose variability as the infusion
site ages.
In this study, we used the glucose
clamp technique to determine whether
the pharmacodynamic proﬁles of aspart
insulindifferedwhenthesamebolusdose
of insulin was delivered through the infu-
sionsetafter12h(day1)and84h(day4)
of use. We also examined whether the
pharmacodynamic proﬁles differed
whether lispro or aspart was used in CSII.
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METHODS— Seventeen subjects
with type 1 diabetes (8 boys and 9 girls)
who attended the Yale Children’s Type 1
Diabetes Clinic were studied. Eligibility
criteria included a clinical diagnosis of
type 1 diabetes for at least 1 year’s dura-
tion,agerangingfrom11to17years,CSII
therapy for at least 3 months, A1C
9.0%, BMI 95% for age and sex, and
the ability to comprehend written and
spoken English. Subjects were excluded
for any other medical disease aside from
type 1 diabetes or treated hypothyroid-
ism, use of medications besides insulin
and levothyroxine, pregnancy, breast-
feeding, or not consistently using barrier
methods or abstinence as contraception
or any other condition that in the judg-
ment of the investigators would interfere
with the subject’s or parent’s ability to
provide informed consent or the investi-
gator’s ability to perform the study. The
Yale University Human Investigation
Committee approved the study.
At the initial enrollment visit, the
risks and beneﬁts of the study were ex-
plained, informed consent from the par-
ents and informed assent from the
subjects were obtained, history and phys-
ical examinations were performed, and
A1C was measured by DCA 2000 ana-
lyzer (Bayer, Tarrytown, NY). The sub-
jects were then randomly assigned to
either the aspart (n  8) or lispro (n  9)
groups. There were no signiﬁcant differ-
ences between the aspart and lispro
groupswithrespecttoage(14.32.8vs.
14.5  1.8 years), BMI percentile (66 
24vs.7214),A1C(6.70.5vs.7.1
0.8%),ordurationofdiabetes(5.24vs.
5.5  2.6 years), respectively.
Preparation for glucose clamp
procedure
Each subject enrolled in the study under-
went two euglycemic clamp procedures
on day 1 (12 h after infusion set inser-
tion) and day 4 (84 h after infusion set
insertion). Subjects were admitted on the
evening before both euglycemic clamp
studies to the Yale Center for Clinical In-
Figure 1—Pharmacodynamic proﬁles. Insulin action, as expressed as GIR, required to maintain
euglycemia after a standard bolus of 0.2 unit/kg insulin aspart or lispro. Data are presented as
means  SEM. A: Day 1 of catheter site insertion. B: Day 4 of catheter site insertion.
Table 1—Mean plasma glucose levels at baseline and during the clamp procedure
Day 1 Day 4
Aspart Lispro P Aspart Lispro P
Baseline plasma glucose (mg/dl) 128  41 145  44 0.42 108  21 142  41 0.05
Plasma glucose during clamp (mg/dl) 99  12 102  11 0.65 98  7 103  11 0.27
Data are means  SD.
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of child-bearing potential were screened
with a urine pregnancy test. For the ﬁrst
study, a new subcutaneous insulin infu-
sion set was placed at the time of admis-
sion in a gluteal location, and they were
readmittedforthesecondclampstudyaf-
ter 3 days’ use of the same infusion set.
Subjects continued to use their own insu-
lin pump and type of infusion set and ei-
ther aspart or lispro insulin depending on
random assignment. An intravenous
catheter was inserted in the forearm for
overnight blood sampling. Plasma glu-
coselevelswerecheckedeveryhourover-
night, and the insulin infusion via CSII
was adjusted to achieve target fasting glu-
cose levels between 80 and 120 mg/dl at
the start of the clamp the next morning.
Glucose clamp procedure
The following morning a second intrave-
nous catheter was inserted in the con-
tralateral forearm, and baseline samples
were obtained for plasma glucose. The
subjects then received a 0.2 unit/kg bolus
of aspart or lispro insulin through the in-
sulin pump, and the pump was sus-
pended. A variable rate of 20% dextrose
solution was used to clamp the plasma
glucose at the desired target of 80–90
mg/dl for 5 h, as described previously
(10,11). Plasma glucose levels were mea-
suredatthebedsideevery5minusingthe
YSI 2300 glucose analyzer (YSI Life Sci-
ences, Yellow Springs, OH). The original
intentwastoanalyzethepharmacokinetic
data; however, because of sample han-
dling problems in several studies, insulin
levels were only available for four aspart
and six lispro subjects, therefore prevent-
ing this analysis.
Changes in the rates of exogenous
glucose infusion were adjusted, as
needed, every 5 min throughout the
study. The study was terminated at5ho r
20 min after the infusion of exogenous
glucose was discontinued. At the comple-
tion of the clamp, the subjects received a
meal,andtheinsulinpumpwasrestarted.
Subjects were instructed to preserve the
insertion catheter currently in use until
readmission to the Clinical Research Unit
3 days later. Some subjects, in whom an
immediate readmission could not be ar-
ranged, were restudied with an infusion
set that they had inserted at home 84 h
before study. The subjects then under-
went a second clamp procedure identical
to the ﬁrst.
Calculations and statistical methods
Thepharmacodynamicparametersevalu-
ated were area under the curve of the glu-
cose infusion rate (AUCGIR), maximum
glucose infusion rate (GIRmax), time to
maximum glucose infusion rate (TmaxGIR),
timetodiscontinuationofexogenousglu-
cose infusion, time to half-maximal in-
crease of peak action (Ti50), and time to
half-maximal decrease from peak action
(Td50).
Fisher’sexacttestandunpairedttests
were used where applicable to compare
the clinical data, initial blood glucose val-
ues, and mean clamp blood glucose val-
ues, which are reported as means  SD.
The t test is fairly robust to the assump-
tion of normality. Nevertheless, we per-
formed Wilcoxon rank-sum tests and
Wilcoxon signed-rank tests. The results
of these nonparametric tests did not alter
the conclusions that were apparent from
parametric testing. We therefore present
means, P values, and 95% CIs based on
the assumptions of the parametric model
to compare pharmacodynamic outcome
measures for both between- and within-
subject comparisons where applicable.
RESULTS— Except for higher base-
lineplasmaglucoselevelswithlisprothan
with aspart on day 4, there were no other
statistically signiﬁcant differences in the
baseline or mean plasma glucose values
during the euglycemic clamp studies,
both within and between groups (Table 1).
As shown in Fig. 1, GIR curves for aspart
and lispro were nearly identical in both
day 1 and day 4 studies. As shown in Ta-
ble 2, there were no statistically signiﬁ-
cant differences in AUCGIR, TmaxGIR,
GIRmax, time to discontinuation of exog-
enousglucoseinfusion,Ti50,orTd50be-
tween subjects treated with aspart and
lispro when they were compared with
each other during day 1 and day 4. Con-
sequently, aspart and lispro results were
combined to examine the effect of dura-
tion of infusion set use on the time-action
proﬁles of these rapid-acting insulins. As
shown in Fig. 2, prolonged use of an in-
sulin infusion site had a substantial effect
on the pharmacodynamic proﬁle of the
same dose of rapid-acting insulin. The
TmaxGIR,timetodiscontinuationofexog-
enous glucose infusion, Ti50, and Td50
were observed signiﬁcantly earlier during
day4comparedwithday1ofinfusionsite
use (Table 3), whereas there were no sta-
tistically signiﬁcant differences in total
AUCGIR or GIRmax at day 1 and day 4.
CONCLUSIONS — This study was
undertakentoexaminewhethertherewas
any effect of increasing duration of infu-
sion site use on the absorption and time-
action proﬁle of a standard 0.2 unit/kg
body weight dose of rapid-acting insulin
analogs in CSII-treated adolescents. We
also examined whether and to what ex-
tent the effect of infusion site age differed
between aspart and lispro insulin. The
ﬁrstclampstudywasperformed12hafter
the placement of a new infusion set (day
1) to allow the infusion site time to re-
cover from the trauma of catheter inser-
tion. The second study was performed
after 84 h, because in clinical practice pa-
tients routinely use the same infusion site
for 3–4 days.






P Aspart Lispro Difference (95% CI) Aspart Lispro Difference (95% CI)
AUCGIR (mg/kg) 982  83 919  175 63 (341 to 467) 0.76 839  124 854  116 15 (354 to 325) 0.93
GIRmax (mg   kg
1   min
1) 7.3  0.6 6.4  1.1 0.96 (1.57 to 3.49) 0.46 7.7  0.9 7.3  1.0 0.39 (2.38 to 3.16) 0.78
TmaxGIR (min) 101  99 2  11 9 (19 to 37) 0.53 79  97 9  7 0.14 (23 to 22) 0.99
Time to discontinuation of
exogenous glucose (min) 263  10 246  15 16 (21 to 54) 0.40 208  20 214  17 6 (58 to 45) 0.81
Ti50 (min) 58  64 6  51 2 ( 3 to 27) 0.14 38  43 9  41 ( 12 to 9) 0.79
Td50 (min) 199  13 191  12 8 (27 to 42) 0.66 136  10 168  13 32 (64 to 0.58) 0.07
Data are means  SE unless indicated otherwise.
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study are that more prolonged use of an
infusion site resulted in earlier peak ac-
tion and shorter duration of action of a
standard bolus dose, whereas the overall
area under the curve of insulin action did
not differ. Moreover, a similar change in
pharmacodynamic characteristics is seen
with both aspart and lispro insulin. Our
data indicating that there is earlier peak
action of insulin with increasing duration
of infusion site use could be the result of
increased blood ﬂow around the infusion
site due to changes in the vascular micro-
environment. Some loss of insulin due to
precipitation in the set or partial occlu-
sion of the infusion set by insulin cannot
beexcludedascontributingfactors.How-
ever, precipitation and occlusion alone
would not explain the earlier peak action
or the similar total AUCGIR values on day
4 versus day 1.
It is important to note that the earlier
onset and shorter duration of bolus doses
on day 4 do not, in themselves, have neg-
ative clinical implications. Indeed, it
couldbearguedthattheresponsesonday
4 are more favorable than those on day 1
with respect to control of meal-related
glucose excursions. Earlier onset and
shorter duration are reasons that rapid-
acting insulin analogs are felt to be supe-
rior to regular insulin in this regard. The
negativeimplicationofthisstudyforclin-
ical practice is that the duration of infu-
sion site use is yet another factor, like
puberty (10), that may contribute to day-
to-day variability and plasma glucose la-
bility in adolescents with type 1 diabetes.
Conversely, more frequent site changes
could lead to more consistent pharmaco-
dynamic proﬁles. These ﬁndings also
raise the question whether duration of in-
fusion site use affects the consistency and
reproducibility of pharmacodynamic re-
sponses to the same bolus dose in the
samesubjectandwhethersimilarchanges
in pharmacodynamic properties are seen
in other body regions (e.g., abdominal
sites).
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